Table 1 Clinical characteristics.

From: Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL

 

Total

CLL

iNHL

 

N = 15

N = 11

N = 4

Age, median (IQR)

64.0 (62.0–69.0)

64.0 (55.0–71.0)

64.0 (62.0–67.5)

Male Gender, n (%)

12 (80.0)

8 (72.7)

4 (100.0)

iNHL type, n (%)

   

Splenic MZL

-

-

3 (75.0)

Nodal MZL

-

-

1 (25.0)

Ann Arbor stage (for iNHL), n (%)

IV

-

-

4 (100.0)

Binet stage (for CLL), n (%)

A

-

5 (45.5)

 

B

-

3 (27.3)

 

C

-

3 (27.3)

 

Chemotherapy, n (%)

15 (100.0)

11 (100.0)

4 (100.0)

FCR

5 (33.3)

5 (45.5)

0 (0.0)

BR

10 (66.7)

6 (54.5)

4 (100.0)

Overall response, n (%)

CR - Complete response

8 (57.1)

7 (70.0)

1 (25.0)

PR - Partial response

6 (42.9)

3 (30.0)

3 (75.0)

BET cell dose, (x109)

Median (range)

9,5 (3–15.9)

10.41 (4.35–15.9)

5.04 (3–9)

Back to article page